Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients

Inclusion Criteria: * Chronic HBV-infected patients * HBeAg-negative patients * Age \> 18 years * Patients with active chronic hepatitis at the start of the antiviral treatment * Patient with a HBV DNA undetectable (\<70 copies/ml) stable for at least 3 months under entecavir or tenofovir treatment. * Ongoing treatment by entecavir or tenofovir at screening Note: previous treatment with pegylated IFN monotherapy, before the start of entecavir or tenofovir, is acceptable Exclusion Criteria: * Infection by HCV * Infection by HIV-1 and /or HIV-2 * Apart from HBV infection, presence of active infection requiring a specific treatment or a hospitalization * Previous treatment by lamivudine and/or nucleosides analogues * Inactive carrier * Cirrhosis * Other liver disease (notably from alcoholic, metabolic or immunological origin) * History of clinical autoimmune disease or active auto-immune disease * Type I diabetes mellitus * Severe asthma, presently on chronic medications